EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab
Open Access
- 16 July 2022
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (12) , 3335-3337.e1
Abstract
No abstract availableFunding Information
- LEO Pharma Research Foundation
This publication has 8 references indexed in Scilit:
- Biomarkers in atopic dermatitis—a review on behalf of the International Eczema CouncilJournal of Allergy and Clinical Immunology, 2021
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*British Journal of Dermatology, 2020
- EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkersAllergy, 2020
- Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statementJournal of the European Academy of Dermatology and Venereology, 2019
- EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin AAllergy, 2018
- EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patientsJournal of Allergy and Clinical Immunology, 2017
- Atopic Dermatitis Diagnostic Criteria and Outcome Measures for Clinical Trials: Still a MessJournal of Investigative Dermatology, 2011
- Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatmentsJournal of the American Academy of Dermatology, 2007